Methylphenidate treatment induces oxidative stress in young rat brain

Brain Research

Volumn 1078, Issue 1, 2006, Pages 189-197

  Martins, Márcio R ^a   Reinke, Adalisa ^a   Petronilho, Fabrícia C ^a   Gomes, Karin M ^a   Dal Pizzol, Felipe ^a   Quevedo, João ^a  

^a UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

Author keywords

Development; Free radical; Methylphenidate; Oxidative stress; Rat

Indexed keywords

FREE RADICAL; METHYLPHENIDATE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; BRAIN CORTEX; CARBONYLATION; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; DRUG EXPOSURE; DRUG MEGADOSE; HIPPOCAMPUS; LIPID PEROXIDATION; MALE; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; OXIDATIVE STRESS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN DETERMINATION; RAT;

AGE FACTORS; ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; BRAIN; BRAIN CHEMISTRY; CENTRAL NERVOUS SYSTEM STIMULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; MALE; METHYLPHENIDATE; OXIDATIVE STRESS; PROTEIN CARBONYLATION; RATS; RATS, WISTAR; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

ANIMALIA; RATTUS NORVEGICUS;

EID: 33645888679     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2006.01.004     Document Type: Article

References (81)

1. Alexander G.E., DeLong M.R., and Strick P.L. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu. Rev. Neurosci. 9 (1986) 357-381
2. Andersen S.L., Arvanitogiannis A., Pliakas A.M., LeBlanc C., and Carlezon Jr. W.A. Altered responsiveness to cocaine in rats exposed to methylphenidate during development. Nat. Neurosci. 5 (2002) 13-14
3. Berman S.B., and Hastings T.G. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J. Neurochem. 73 (1999) 1127-1137
4. Biederman J., Mick E., and Faraone S.V. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am. J. Psychiatry 157 (2000) 816-818
5. Bolaños C.A., Barrot M., Berton O., Wallace-Black D., and Nestler E.J. Methylphenidate treatment during pre- and periadolescence alters behavioral responses to emotional stimuli at adulthood. Biol. Psychiatry 54 (2003) 1317-1329
6. Brandon C.L., and Steiner H. Repeated methylphenidate treatment in adolescent rats alters gene regulation in the striatum. Eur. J. Neurosci. 18 (2003) 1584-1592
7. Brandon C.L., Marinelli M., Baker L.K., and White F.J. Enhanced reactivity and vulnerability to cocaine following methylphenidate treatment in adolescent rats. Neuropsychopharmacology 25 (2001) 651-661
8. Brown J.M., and Yamamoto B.K. Effects of amphetamines on mitochondrial function: role of free radicals and oxidative stress. Pharmacol. Ther. 99 (2003) 45-53
9. Carlezon Jr. W.A., and Nestler E.J. Elevated levels of GluR1 in the midbrain: a trigger for sensitization to drugs of abuse?. Trends Neurosci. 25 (2002) 610-615
10. Challman T.D., and Lipsky J.J. Methylphenidate: its pharmacology and uses. Mayo Clin. Proc. 75 (2000) 711-721
11. Chan P., Di Monte D.A., Luo J.J., DeLanney L.E., Irwin I., and Langston J.W. Rapid ATP loss caused by methamphetamine in the mouse striatum: relationship between energy impairment and dopaminergic neurotoxicity. J. Neurochem. 62 (1994) 2484-2487
12. Chase T.D., Brown R.E., Carrey N., and Wilkinson M. Daily methylphenidate administration attenuates c-fos expression in the striatum of prepubertal rats. NeuroReport 14 (2003) 769-772
13. Cheeta S., Kenny P.J., and File S.E. Hippocampal and septal injections of nicotine and 8-OH-DPAT distinguish among different animal tests of anxiety. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 24 (2000) 1053-1067
14. Crawford C.A., McDougall S.A., Meier T.L., Collins R.L., and Watson J.B. Repeated methylphenidate treatment induces behavioral sensitization and decreases protein kinase A and dopamine-stimulated adenylyl cyclase activity in the dorsal striatum. Psychopharmacology 136 (1998) 34-43
15. Dal-Pizzol F., Klamt F., Vianna M., Schroder N., Quevedo J., and Benfato M.S. Lipid peroxidation in hippocampus early and late after status epileticus induced by pilocarpine or kainic acid in Wistar rats. Neurosci. Lett. 291 (2000) 179-182
16. Dal-Pizzol F., Klamt F., Frota Jr. M.L.C., Andrades M.E., Caregnato F.F., and Vianna M. Neonatal iron exposure induces oxidative stress in adult Wistar rat. Dev. Brain Res. 130 (2001) 109-114
17. Desmond J.E., and Fiez J.A. Neuroimaging studies of the cerebellum: language, learning, and memory. Trends Cogn. Sci. 2 (1998) 355-362
18. Dougherty D.D., Bonab A.A., Spencer T.J., Rauch S.L., Madras B.K., and Fischman A.J. Dopamine transporter density is elevated in patients with ADHD. Lancet 354 (1999) 2132-2133
19. Draper H.H., and Hadley M. Malondialdehyde determination as index of lipid peroxidation. Methods Enzymol. 186 (1990) 421-431
20. Faraone S.V., Sergeant J., Gillberg C., and Biederman J. The worldwide prevalence of ADHD: is it an American condition?. World Psychiatry 2 (2003) 104-113
21. Federici M., Geracitano R., Bernardi G., and Mercuri N.B. Actions of methylphenidate on dopaminergic neurons of the ventral midbrain. Biol. Psychiatry 57 (2005) 361-365
22. File S.E., Kenny P.J., and Cheeta S. The role of the dorsal hippocampal serotonergic and cholinergic systems in the modulation of anxiety. Pharmacol. Biochem. Behav. 66 (2000) 65-72
23. Fukami G., Hashimoto K., Koike K., Okamura N., Shimizu E., and Iyo M. Effect of antioxidant N-acetyl-L-cysteine on behavioral changes and neurotoxicity in rats after administration of methamphetamine. Brain Res. 1016 (2004) 90-95
24. Fukui R., Svenningsson P., Matsuishi T., Higashi H., Nairn A.C., Greengard P., and Nishi A. Effect of methylphenidate on dopamine/DARPP signalling in adult, but not young, mice. J. Neurochem. 87 (2003) 1391-1401
25. Garland E.J. Pharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices, caveats. J. Psychopharmacol. 12 (1998) 385-395
26. Gerasimov M.R., Franceschi M., Volkow N.D., Rice O., Schiffer W.K., and Dewey S.L. Synergistic interactions between nicotine and cocaine or methylphenidate depend on the dose of dopamine transporter inhibitor. Synapse 38 (2000) 432-437
27. Greenhill L.L. Clinical effects of stimulant medication in attention-deficit/hyperactivity disorder (ADHD). In: Solanto M.V., Arnsten A.F.T., and Castellanos F.X. (Eds). Stimulant Drugs and ADHD: Basic and Clinical Neuroscience (2001), Oxford Univ. Press, New York 31-71
28. Husson I., Mesples B., Medja F., Leroux P., Kosofsky B., and Gressens P. Methylphenidate and MK-801, an N-methyl-d-aspartate receptor antagonist: shared biological properties. Neuroscience 125 (2004) 163-170
29. Kempermann G. Regulation of adult hippocampal neurogenesis-Implications for novel theories of major depression. Bipolar Disord. 4 (2002) 17-33
30. Kim H.S., and Park W.K. Nitric oxide mediation of cocaine-induced dopaminergic behaviors: ambulation-accelerating activity, reverse tolerance and conditioned place preference in mice. J. Pharmacol. Exp. Ther. 275 (1995) 551-557
31. Klamt F., Dal-Pizzol F., Frota Jr. M.L.C., Walz R., Andrades M.E., and Silva E.G. Imbalance of antioxidant defence in mice lacking cellular prion protein. Free Radical Biol. Med. 30 (2001) 1137-1144
32. Koob G.F., Sanna P.P., and Bloom F.E. Neuroscience of addiction. Neuron 21 (1998) 467-476
33. Kuczenski R., and Segal D.S. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J. Neurochem. 68 (1997) 2032-2037
34. Kuczenski R., and Segal D.S. Locomotor effects of acute and repeated threshold doses of amphetamine and methylphenidate: relative roles of dopamine and norepinephrine. J. Pharmacol. Exp. Ther. 296 (2001) 876-883
35. Kuczenski R., and Segal D.S. Exposure of adolescent rats to oral methylphenidate: preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine. J. Neurosci. 22 (2002) 7264-7271
36. Laviola G., Adriani W., Livia Terranova M., and Gerra G. Psychobiological risk factors for vulnerability to psychostimulants in human adolescents and animal models. Neurosci. Biobehav. Rev. 23 (1999) 993-1010
37. LaVoie M.J., and Hastings T.G. Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J. Neurosci. 19 (1999) 1484-1491
38. Levine R.L., Garland D., and Oliver C.N. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol. 186 (1990) 464-478
39. Lou H. Etiology and pathogenesis of attention-deficit hyperactivity disorder (ADHD); significance of prematurity and perinatal hypoxic-haemodynamic encephalopathy. Acta Paediatr. 85 (1996) 1266-1271
40. Lowry O.H., Rosebrough A.L., and Randal R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
41. Mague S.D., Andersen S.L., and Carlezon Jr. W.A. Early developmental exposure to methylphenidate reduces cocaine-induced potentiation of brain stimulation reward in rats. Biol. Psychiatry 57 (2005) 120-125
42. Mannuzza S., Klein R.G., Bessler A., Malloy P., and Hynes M.E. Educational and occupational outcome of hyperactive boys grown up. J. Am. Acad. Child Adolesc. Psychiatry 36 (1997) 1222-1227
43. Mannuzza S., Klein R.G., Bessle A., Malloy P., and LaPadula M. Adult psychiatric status of hyperactive boys grown up. Am. J. Psychiatry 155 (1998) 493-498
44. Marsteller D.A., Gerasimov M.R., Schiffer W.K., Geiger J.M., Barnett C.R., Borg J.S., et al. Acute handling stress modulates methylphenidate-induced catecholamine overflow in the medial prefrontal cortex. Neuropsychopharmacology 27 (2002) 163-170
45. McDougall S.A., Collins R.L., Karper P.E., Watson J.B., and Crawford C.A. Effects of repeated methylphenidate treatment in the young rat: sensitization of both locomotor activity and stereotyped sniffing. Exp. Clin. Psychopharmacol. 7 (1999) 208-218
46. Middleton F.A., and Strick P.L. Cerebellar projections to the prefrontal cortex of the primate. J. Neurosci. 21 (2001) 700-712
47. Moll G.H., Hause S., Ruther E., Rothenberger A., and Huether G. Early methylphenidate administration to young rats causes a persistent reduction in the density of striatal dopamine transporters. J. Child Adolesc. Psychopharmacol. 11 (2001) 15-24
48. Nestler E.J. Molecular basis of long-term plasticity underlying addiction. Nat. Rev., Neurosci. 2 (2001) 119-128
49. Page G., Peeters M., Najimi M., Maloteaux J.M., and Hermans E. Modulation of the neuronal dopamine transporter activity by the metabotropic glutamate receptor mGluR5 in rat striatal synaptosomes through phosphorylation mediated processes. J. Neurochem. 76 (2001) 1282-1290
50. Penner M.R., McFadyen M.P., Pinaud R., Carrey N., Robertson H.A., and Brown R.E. Age-related distribution of c-fos expression in the striatum of CD-1 mice after acute methylphenidate administration. Brain Res. Dev. Brain Res. 135 (2002) 71-77
51. Prehn J.H. Mitochondrial transmembrane potential and free radical production in excitotoxic neurodegeneration. Naunyn-Schmiedeberg's Arch. Pharmacol. 357 (1998) 316-322
52. Przegalinski E., and Filip M. Nitric oxide (NO) pathway and locomotor hyperactivity towards dopaminomimetics in rats. Pol. J. Pharmacol. 49 (1997) 291-298
53. Pudiak C.M., and Bozarth M.A. The effect of nitric oxide synthesis inhibition on intravenous cocaine self-administration. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 26 (2002) 189-196
54. Robinson T.E., and Becker J.B. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res. Rev. 11 (1986) 157-198
55. Robinson T.E., and Berridge K.C. The psychology and neurobiology of addiction: an incentive-sensitization view. Addiction 95 (2000) 91-117
56. Safer D.J., and Allen R.P. Absence of tolerance to the behavioral effects of methylphenidate in hyperactive and inattentive children. J. Pediat. 115 (1989) 1003-1008
57. Sax K.W., and Strakowski S.M. Enhanced behavioral response to repeated D-amphetamine and personality traits in humans. Biol. Psychiatry 44 (1998) 1192-1195
58. Schenk S., and Davidson E. Stimulant pre-exposure sensitizes rats and humans to the rewarding effects of cocaine. NIDA Res. Monogr. 169 (1998) 56-82
59. Schinder A.F., Olson E.C., Spitzer N.C., and Montal M. Mitochondrial dysfunction is a primary event in glutamate neurotoxicity. J. Neurosci. 16 (1996) 6125-6133
60. Schmahmann J.D., and Sherman J.C. The cerebellar cognitive affective syndrome. Brain 121 (1998) 561-579
61. Schweitzer J.B., Lee D.O., Hanford R.B., Zink C.F., Ely T.D., Tagamets M.A., et al. Effect of methylphenidate on executive functioning in adults with attention-deficit/hyperactivity disorder: normalization of behavior but not related brain activity. Biol. Psychiatry 56 (2004) 597-606
62. Schweri M.M., Skolnick P., Rafferty M.F., Rice K.C., Janowsky A.J., and Paul S.M. [3H]Threo-(+/-)-methylphenidate binding to 3,4-dihydroxyphenylethylamine uptake sites in corpus striatum: correlation with the stimulant properties of ritalinic acid esters. J. Neurochem. 45 (1985) 1062-1070
63. Segal D.S., and Kuczenski R. Behavioral pharmacology of amphetamine. In: Cho A.K., and Segal D.S. (Eds). Amphetamine and its Analogues: Psychopharmacology, Toxicology and Abuse (1994), Academic, San Diego 115-150
64. Setnik B., and Nobrega J.N. Long-chain acyl-CoenzymeA synthetase-2 mRNA: increased cerebral cortex expression in an animal model of depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 28 (2004) 577-582
65. Shah A.A., and Treit D. Infusions of midazolam into the medial prefrontal cortex produce anxiolytic effects in the elevated plus-maze and shock-probe burying tests. Brain Res. 996 (2004) 31-40
66. Shah A.A., Sjovold T., and Treit D. Inactivation of the medial prefrontal cortex with the GABA A receptor agonist muscimol increases open-arm activity in the elevated plus-maze and attenuates shock-probe burying in rats. Brain Res. 1028 (2004) 112-115
67. Spina M.B., and Cohen G. Dopamine turnover and glutathione oxidation: implications for Parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 86 (1989) 1398-1400
68. Strakowski S.M., and Sax K.W. Progressive behavioral response to repeated d-amphetamine challenge: further evidence for sensitization in humans. Biol. Psychiatry 44 (1998) 1171-1177
69. Strakowski S.M., Sax K.W., Rosenberg H.L., DelBello M.P., and Adler C.M. Human response to repeated low-dose d-amphetamine: evidence for behavioral enhancement and tolerance. Neuropsychopharmacology 25 (2001) 548-554
70. Talpalar A.E., and Grossman Y. Enhanced excitability compensates for high-pressure-induced depression of cortical inputs to the hippocampus. J. Neurophysiol. 92 (2004) 3309-3319
71. Taylor F.B., and Russo J. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. J. Clin. Psychopharmacol. 21 (2001) 223-228
72. Vanderschuren L.J.M.J., and Kalivas P.W. Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies. Psychopharmacology 151 (2000) 99-120
73. Virmani A., Gaetani F., Imam S., Binienda Z., and Ali S. The protective role of l-carnitine against neurotoxicity evoked by drug of abuse, methamphetamine, could be related to mitochondrial dysfunction. Ann. N. Y. Acad. Sci. 965 (2002) 225-232
74. Volkow N.D., Wang G.-J., Fowler J.S., Gatley S.J., Logan J., and Ding Y.-S. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am. J. Psychiatry 155 (1998) 1325-1331
75. Volkow N.D., Wang G.J., Fowler J.S., Fischman M., Foltin R., and Abumrad N.N. Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain. Life Sci. 65 (1999) 7-12
76. Volkow N.D., Wang G., Fowler J.S., Logan J., Gerasimov M., and Maynard L. Therapeutic doses of oral methylphenidate significantly increases extracellular dopamine in the human brain. J. Neurosci. 21 (2001) 121
77. Volkow N.D., Fowler J.S., Wang G.J., Ding Y.S., and Gatley S.J. Role of dopamine in the therapeutic and reinforcing effects of methylphenidate in humans: results from imaging studies. Eur. Neuropsychopharmacol. 12 (2002) 557-566
78. Volkow N.D., Wang G., Fowler J.S., and Ding Y. Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol. Psychiatry 57 (2005) 1410-1415
79. Wigal T., Swanson J.M., Regino R., Lerner M.A., Soliman I., and Steinhoff K. Stimulant medications for the treatment of ADHD: efficacy and limitations. Ment. Retard. Dev. Disabil. Res. Rev. 5 (1999) 215-224
80. Wise R.A., and Bozarth M.A. A psychomotor stimulant theory of addiction. Psychol. Rev. 94 (1987) 469-492
81. Zhong P., and Yan Z. Chronic antidepressant treatment alters serotonergic regulation of GABA transmission in prefrontal cortical pyramidal neurons. Neuroscience 129 (2004) 65-73